447 related articles for article (PubMed ID: 25199960)
1. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
[TBL] [Abstract][Full Text] [Related]
4. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
Pathomrattanapiban C; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S
Mult Scler Relat Disord; 2022 Jul; 63():103882. PubMed ID: 35598463
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
Jacob A; Matiello M; Weinshenker BG; Wingerchuk DM; Lucchinetti C; Shuster E; Carter J; Keegan BM; Kantarci OH; Pittock SJ
Arch Neurol; 2009 Sep; 66(9):1128-33. PubMed ID: 19752302
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
Front Immunol; 2018; 9():2066. PubMed ID: 30258442
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
Songwisit S; Kosiyakul P; Jitprapaikulsan J; Prayoonwiwat N; Ungprasert P; Siritho S
Sci Rep; 2020 Oct; 10(1):16727. PubMed ID: 33028926
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints.
Jeong IH; Park B; Kim SH; Hyun JW; Joo J; Kim HJ
Mult Scler; 2016 Mar; 22(3):329-39. PubMed ID: 26041804
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of mycophenolate mofetil in treating neuromyelitis optica spectrum disorder: a multicenter, prospective, self-control study in Guangzhou City].
Huang Q; Wang YG; Shu YQ; Yang H; Wang ZH; Yan ZW; Long YM; Yin J; Feng HY; Li CX; Lu ZZ; Hu XQ; Qiu W
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(21):1664-1668. PubMed ID: 29925143
[No Abstract] [Full Text] [Related]
15. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
Cao S; Yu H; Tian J; Li Y; Shen Y; Ji X; Wang X; Zhou X; Gu Y; Zhu F; Duan X; Xiao X; Fang Q; Chen X; Xue Q
J Neurol Sci; 2021 Oct; 429():117616. PubMed ID: 34450520
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
Espiritu AI; Pasco PMD
Mult Scler Relat Disord; 2019 Aug; 33():22-32. PubMed ID: 31136907
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.
Akatani R; Chihara N; Koto S; Mori S; Kurimoto T; Nakamura M; Tachibana H; Otsuka Y; Ueda T; Omori T; Sekiguchi K; Matsumoto R
Immunol Med; 2024 Jun; 47(2):85-92. PubMed ID: 38235761
[TBL] [Abstract][Full Text] [Related]
19. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
Shi Z; Du Q; Chen H; Zhang Y; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
J Neurol; 2020 Apr; 267(4):913-924. PubMed ID: 31776721
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
Dresser L; Chaar WA; Reder AT; Abuaf AF; Cipriani VP; Javed A
Mult Scler Relat Disord; 2023 Jun; 74():104718. PubMed ID: 37086634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
